<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744470</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO2011/YL/ADEQUATE</org_study_id>
    <secondary_id>2011-003184-29</secondary_id>
    <nct_id>NCT01744470</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)</brief_title>
  <acronym>ADEQUATE</acronym>
  <official_title>Efficacy and Safety Outcome of Two Different Targets of Advagraf® Trough Levels Between 4 Months and 12 Months After Transplantation Among de Novo Renal Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, interventional, open label, randomized, multicenter study was designed to
      determine the risk/benefit ratio of a 50 % reduction of Advagraf® daily dose, 4 months after
      transplantation. Randomized patients are to be stable with their tacrolimus daily dose
      required to reach targeted tacrolimus trough levels. Based on Month-3 eligibility
      assessments, patients will be randomized in two groups (1:1): patients with 50 % reduction of
      the daily dose of Advagraf® 4 months after transplantation, and patients kept on their usual
      dose. The benefit/risk ratio will include the assessment of renal function, histological
      lesions from both alloreactivity and CNI nephrotoxicity, and safety data (metabolic and
      infectious diseases).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function at one year post transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Renal function at one year post transplantation estimated by the glomerular filtration rate (GFR) using MDRD 4 (Modification Diet in Renal Disease). Crude difference in renal function at one year between groups and the change of renal function between 4 months and one year in each group will be analyzed and compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Routine graft histology at M12 assessed using Banff 2009 classification, with specific analysis of interstitial fibrosis (IF) using numeric quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Glucose metabolism at M4 and M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Infection rate including BKV and CMV at M4 and M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Presence and intensity of Donor Specific Antibody (DSA) at M3 and M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of biopsy proven acute rejection episode at M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Graft and patient survival at M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare according to randomized group</measure>
    <time_frame>12 months</time_frame>
    <description>Overall safety assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">286</enrollment>
  <condition>De Novo Transplant Disease</condition>
  <arm_group>
    <arm_group_label>Group A - tacrolimus half-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.
Drug: Tacrolimus targeted half-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - tacrolimus unchanged dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus targeted half-dose</intervention_name>
    <arm_group_label>Group A - tacrolimus half-dose</arm_group_label>
    <other_name>Advagraf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus targeted plain dose</intervention_name>
    <arm_group_label>Group B - tacrolimus unchanged dose</arm_group_label>
    <other_name>Advagraf®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 et 70 years

          -  Patient accepting to give a written informed consent

          -  Recipients of a first renal allograft

          -  Cadaver or living transplantation or living (non HLA identical) donor with compatible
             ABO blood type.

          -  Absence of positive DSA using Luminex®, MFI&gt;1,000

          -  Negative cross-match in cytotoxicity

          -  Patient without difficulty to understand and communicate with the investigator and his
             collaborators

          -  Patient entitled to Health System benefits or other such benefits.

        Exclusion Criteria:

          -  Multiple organ transplantation

          -  Recipients of a dual kidney transplant

          -  Previous renal allograft

          -  History of any other transplantation

          -  Receiving a graft from a non-heart-beating donor

          -  Patient BMI &gt; 35

          -  Patients with evidence of severe liver disease, including abnormal liver profile (AST,
             ALT, or total bilirubin &gt; 3 times upper limit of normal) at screening.

          -  Significant severe infection, active peptic ulcer and/or difficulty to absorb oral
             drugs (active upper gastro-intestinal tract malabsorption syndrome)

          -  HIV-positive patients, or with an active B or C hepatitis

          -  Patients with de novo malignancy prior to transplantation, other than efficiently
             treated basal or squamous cell carcinoma of the skin.

          -  Leucocyte count lower than 2500/mm3

          -  Female patients who are pregnant, lactating or of child bearing potential and not
             practicing an approved method of birth control.

          -  Known allergy or intolerance to basiliximab, tacrolimus, macrolide antibiotics,
             corticosteroids, or mycophenolate mofetil or any of the product excipients

          -  Participation in a clinical trial or expanded access trial with an investigational
             drug within 4 weeks prior to enrollment or concomitantly with this study

          -  Any clinical condition which, in the opinion of the investigator, would not allow safe
             completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon LEBRANCHU</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bois-Guillaume</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

